Modifications of the behavioral profile of non-competitive NMDA receptor antagonists, memantine, amantadine and (+)MK-801 after chronic administration

Behavioural Pharmacology

Volumn 10, Issue 1, 1999, Pages 85-98

  Hesselink, M B ^a,b   Smolders, H ^a,b   De Boer, A G ^b   Breimer, D D ^b   Danysz, W ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

(+)MK 801; Amantadine; Ataxia; Catalepsy; Chronic treatment; Learning impairment; Locomotor activation; Memantine; NMDA receptor; Rat

Indexed keywords

AMANTADINE; DIZOCILPINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR MODIFICATION; CONTINUOUS INFUSION; DRUG POTENCY; DRUG TOLERANCE; LEARNING DISORDER; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PASSIVE AVOIDANCE; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0033047303     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-199902000-00008     Document Type: Article

References (47)

1. Anis NA, Berry SC, Burton NR, Lodge D (1983). The dissociative anesthetics ketamine and phencyclidine, selectively inhibit excitation of central mammalian neurons by N-methylaspartate. Br J Pharmacol 79:565-575.
2. Beart PM, Lodge D (1990). Chronic administration of MK-801 and the NMDA receptor: further evidence for reduced sensitivity of the primary acceptor site from studies with the cortical wedge preparation. J Pharm Pharmacol 42:354-355.
3. Bennett DA, Amrick CL (1986). 2-amino-7-phosphoheptanoic acid (AP7) produces discriminative stimuli and anticonflict effects similar to diazepam. Life Sci 39:2455-2461.
4. Block F, Schwarz M (1996). Memantine reduces functional and morphological consequences induced by global ischemia in rats. Neurosci Lett 208:41-44.
5. Collingridge GL, Singer W (1990). Excitatory amino acid receptors and synaptic plasticity. Trends in Pharmacol Sci 11:290-296.
6. Cotman CW, Monaghan DT (1988). Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity. Ann Rev Neurosci 11:61-80.
7. Dall'Olio R, Gandolfi O, Montanaro N (1992). Effect of chronic treatment with dizocilpine (MK-801) on the behavioral response to dopamine receptor agonists in the rat. Psychopharmacol 107:591-594.
8. Danysz W, Essmann U, Bresink I, Wilke R (1994a). Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol Biochem Behav 48:111-118.
9. Danysz W, Gossel M, Zajaczkowski W, Dill D, Quack G (1994b). Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? The case of amantadine and memantine. J Neural Transm - Park Dis Dement Sect 7:155-166.
10. Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G (1997). Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies. Neurosci and Biobehav Rev 21:455-468.
11. Eisenberg E, Lacross S, Strassman AM (1995). The clinically tested N-methyl-D-aspartate receptor antagonist memantine blocks and reverses thermal hyperalgesia in a rat model of painful mononeuropathy. Neurosci Lett 187:17-20.
12. Genovese RF, Lu XCM (1991). Effects of MK-801 stereo-isomers on schedule-controlled behavior in rats. Psychopharmacol 105:477-480.
13. Gill R, Brazell C, Woodruff GN, Kemp JA (1991). The neuroprotective action of dizocilpine (MK-801) in the rat middle cerebral artery occlusion model of focal ischaemia. Br J Pharmacol 103:2030-2036.
14. 2, but not of muscarinic receptors following 14 days administration of uncompetitive NMDA receptor antagonists. J Neural Transm (in press).
15. Honey CR, Miljkovic Z, MacDonald JF (1985). Ketamine and phencyclidine cause a voltage-dependent block of responses to I-aspartic acid. Neurosci Lett 61:135-139.
16. Kalivas PW (1995). Interactions between dopamine and excitatory amino acids in behavioral sensitization to psychostimulants. Drug Alcohol Depend 37:95-100.
17. Kampman K, Volpicelli JR, Alterman A, Cornish J, Weinrieb R, Epperson L, Sparkman T, Obrien CP (1996). Amantadine in the early treatment of cocaine dependence: a double-blind, placebo-controlled trial. Drug Alcohol Depend 41:25-33.
18. Kuribara H, Asami T, Ida I, Iijima Y, Tadokoro S (1992). Effects of repeated MK-801 on ambulation in mice and in sensitization following methamphetamine. Psychopharmacol 108:271-275.
19. Kurumaji A, Ikeda M, Dewar D, McCormack A, McCulloch J (1991). Effects of chronic administration of MK-801 upon local cerebral glucose utilisation and ligand binding to the NMDA receptor complex. Brain Res 563:57-65.
20. Lannes B, Bernard V, Bloch B, Micheletti G (1995). Chronic treatment with dizocilpine maleate increases the number of striatal neurons expressing the d-2 receptor gene. Neurosci 65:431-438.
21. Lannes B, Micheletti G, Warter JM, Kempf E, Di Scala G. (1991). Behavioural, pharmacological and biochemical effects of acute and chronic administration of ketamine in the rat. Neurosci Lett 128:177-181.
22. Leccese AP, Marquis KL, Mattia A, Moreton JE (1986). The anticonvulsant and behavioral effects of phencyclidine and ketamine following chronic treatment in rats. Behav Brain Res 22:257-264.
23. Leppik IE, Marienau K, Graves NM, Rask CA (1988). MK-801 for epilepsy: a pilot study. Neurology 38 (Suppl. 1):405.
24. Löscher W (1993). Basic aspects of epilepsy. Curr Opin Neurol Neurosur 6:223-232.
25. Löscher W, Honack D (1992). The behavioural effects of MK-801 in rats - involvement of dopaminergic, serotonergic and noradrenergic systems. Eur J Pharmacol 215:199-208.
26. 3H]D-AP5, suggesting down-regulation of the cortical N-methyl-D-aspartate receptors. Neurosci 30:87-94.
27. Micheletti G, Lannes B, Haby C, Borrelli E, Kempf E, Warter JM, Zwiller J (1992). Chronic administration of NMDA antagonists induces D2 receptor synthesis in rat striatum. Mol Brain Res 14:363-368.
28. Misztal M, Danysz W (1995). Comparison of glutamate antagonists in continuous multiple-trial and single-trial dark avoidance. Behav Pharmacol 6:550-561.
29. Misztal M, Frankiewicz T, Parsons CG, Danysz W (1996). Learning deficits induced by chronic intraventricular infusion of quinolinic acid - protection by MK-801 and memantine. Eur J Pharmacol 296:1-8.
30. Norman AB, Ford LM, Kolmonpunporn M, Sanberg PR (1990). Chronic treatment with MK-801 increases the quinolinic acid-induced loss of D-1 dopamine receptors in rat striatum. Eur J Pharmacol 176:363-366.
31. Ossowska K (1994). The role of excitatory amino acids in experimental models of Parkinson's disease. J Neural Transm - Park Dis Dement Sect 8:39-71.
32. Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, Krzascik P, Hartmann S, Danysz W (1995). Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacol 34:1239-1258.
33. Paxinos G, Watson C (1986). The Rat's Brain in Stereotaxic Coordinates. New York: Academic Press.
34. Pechnick RN, Hiramatsu M (1994). The effects of MK-801 on body temperature and behavior in the rat - cross-sensitization and cross-tolerance with phencyclidine. Eur J Pharmacol 252:35-42.
35. Popik P, Skolnick P (1996). The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol Biochem Behav 53:791-797.
36. Scatton B (1994). Excitatory amino acid receptor antagonists: a novel treatment for ischemic cerebrovascular diseases. Life Sci 55:2115-2124.
37. Schmidt WJ, Bubser M (1989). Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol Biochem Behav 32:621-623.
38. Schwartz PH, Wasterlain CG (1993). Determination of serum and brain concentrations of neuroprotective and nonneuroprotective doses of MK-801. J Neurolog Sci 115:26-31.
39. Soares JC, Gershon S (1994). Advances in the pharmacotherapy of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 244:261-271.
40. Starr MS (1995). Antiparkinsonian actions of glutamate antagonists - alone and with 1-DOPA: a review of evidence and suggestions for possible mechanisms. J Neural Transm -Park Dis Dement Sect 10:141-185.
41. Stephens DN (1995). A glutamatergic hypothesis of drug dependence: extrapolations from benzodiazepine receptor ligands. Behav Pharmacol 6:425-446.
42. Trujillo KA (1995). Effects of noncompetitive N-methyl-D-aspartate receptor antagonists on opiate tolerance and physical dependence. Neuropsychopharmacol 13:301-307.
43. Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM, Prasad M, Rajput A, Basran P (1996). Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 46:1551-1556.
44. Vezzani A, Serafini R, Stasi MA, Caccia S, Conti I, Tridico RV, Samanin R (1989). Kinetics of MK-801 and its effect on quinolinic acid-induced seizures and neurotoxicity in rats. J Pharmacol Exp Ther 249:278-283.
45. Wenk GL, Danysz W, Roice DD (1996). The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis. NeuroReport 7:1453-1456.
46. Wessinger WD (1994). Tolerance to and dependence on MK-801 (dizocilpine) in rats. Pharmacol Biochem Behav 49:1049-1056.
47. Willis CL, Brazell C, Foster AC (1991). Plasma and CSF levels of dizocilpine (MK-801) required for neuroprotection in the quinolinate-injected rat striatum. Eur J Pharmacol 196:285-290.